Navigation Links
ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:3/12/2008

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that preliminary data from the Company's Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of advanced breast cancer has been accepted for presentation at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.

The poster presentation entitled "5,10 methylenetetrahydrofolic acid with 5-fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase 2 study," is scheduled to be presented on June 2, 2008.

About ANX-510, or CoFactor

CoFactor is a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-fluorouracil). Compared to leucovorin, CoFactor creates more stable binding between the active form of 5-FU and the target enzyme, thymidylate synthase. CoFactor bypasses the metabolic pathway required by leucovorin to deliver the active form of folate, potentially allowing 5-FU to work more effectively.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
2. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Genzyme Announces Presentation of New Positive Data on Carticel(R)
7. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
8. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
9. SpineSmith Partners to Present at 3rd Annual Stem Cell Summit
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014  Heska Corporation (Nasdaq: ... Invites You to Join Its Third Quarter 2014 Earnings ... 9:00 a.m. (MDT) / 11:00 a.m. (EDT)Where: , ... link on the front page of this website)How:Live over ... at the address above.  Alternatively, you may use the ...
(Date:10/25/2014)... --  Metanome, Inc. , a Houston ... was the genomic sequencing provider for Seres Health,s ( ... of SER 109, an Ecobiotic® therapeutic for the treatment ... (CDI). Metanome has provided genomic sequencing services ... Such genomic characterization has enabled the study of the ...
(Date:10/25/2014)... , Oct. 24, 2014 Best ... Medical Affairs leaders with a forum for sharing ... consortium has developed a mechanism for creating and ... leaders discuss key findings from the Medical Affairs ... completed the analysis for the first roundtable of ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... ,   Amcor ... €6.7 million in its Singen converting plant ... production of pharmaceutical packaging,and upgrades the classic ... industry.      (Logo:  http://www.newscom.com/cgi-bin/prnh/20110630/465056  ) ...
... June 29, 2011 CardioGenics Holdings Inc. (CGNH.OB) ... Trademark Office (USPTO) has notified the company that ... # 7,964,415). This patent covers ... is a key component of the core technology ...
Cached Medicine Technology:Amcor Invests €6.7 Million in the Extension of its Singen Converting Plant in Germany 2USPTO Issues Patent for CardioGenics' Signal Amplification Technology 2
(Date:10/25/2014)... (PRWEB) October 25, 2014 Background: , ... Recovery (CCAR). He is a pioneer in the field of ... in Connecticut's state treatment system and when he retired, he ... him while in public service. , 1. ... critical decisions concerning them? , 2. Can the recovery ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... New York (PRWEB) October 25, 2014 ... mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against ... underway in U.S. District Court, Southern District of ... Summary Judgment on Punitive Damages in a group ... In a ruling issued on October 21st, U.S. ...
(Date:10/25/2014)... (HealthDay News) -- Interrupting blood supply to an arm or ... associated with the surgery, according to a new study. ... supply to the heart to be able to operate on ... reduce its ability to produce energy because it doesn,t get ... large muscle, such as an arm or a leg, the ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... increasingly important method for detecting malaria. Health specialists recommend ... other strategies for controlling the disease // , including ... indoor spraying against malaria-carrying mosquitoes and testing and treatment ... tests are ideal for rural areas are accurate, easy ...
... Researchers find that aspirin saves the life of cancer ... believe that majority of these patients will die// if ... turns common medical assumptions upside down and will likely ... thin blood and cancer patients experience low platelet counts ...
... The experts in this weeks' BMJ, have reported that ... work together to restore faith in drug development//. ... drug Vioxx, produced by Merck and Co. Inc., has ... be open to abuse. ,Vioxx (rofecoxib) ...
... explains - how beneficial traits accumulate in natural populations, but ... two theories have addressed this problem. The theory of hitchhiking ... can become common in natural populations when they "hitch a ... selection. ,Conversely, the theory of kin selection ...
... Drugs that Facilitate and/or Prevent Diabetes//. ... develop new-onset diabetes than those who don’t have hypertension, ... recent weight gain, or stronger family history of diabetes ... have known since 1958 that some drugs used to ...
... children with persistent fluid in the middle ear// need not ... , It is generally believed that ear fluid has to ... study suggests that inserting ear tubes to remove ear fluid ... years of age. This important study was conducted at Children’s ...
Cached Medicine News:Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3Health News:Aspirin Saves Life Even in Cancer Patients 2Health News:Aspirin Saves Life Even in Cancer Patients 3Health News:New Approach Needed To Restore Faith in Pharmaceutical Industry 2Health News:Study Explains How Costly Traits Evolve 2Health News:Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified 2Health News:Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified 3Health News:Ear Fluid Does Not Impair Development 2Health News:Ear Fluid Does Not Impair Development 3Health News:Ear Fluid Does Not Impair Development 4
Sandhill Scientific offers a comprehensive selection of solid state and water perfused catheters for both adult & pediatric applications.Contact Sandhill Scientific for full details...
... of single-use products to promote safety for ... single-use catheter reduces cross-contamination and helps protect ... and, because cleaning is eliminated, you have ... have water perfused manometric catheters for esophageal, ...
... Air-Charged Catheters make motility ... Disposable Latitude catheters set up ... cross-contamination. And with every sensor ... by eliminating anatomical irregularities. For ...
Polygraf ID Adapter Cable for LATITUDE® Air-Charged Catheter...
Medicine Products: